[Form 4] PROVECTUS BIOPHARMACEUTICALS, INC. Insider Trading Activity
Rhea-AI Filing Summary
Edward Pershing, CEO and Director of Provectus Biopharmaceuticals, Inc. (PVCT), converted a 2024 unsecured convertible promissory note into equity on September 19, 2025. The $100,000 8% note, originally issued under the companys 2024 financing and convertible at $2.862 per share into Series D-1 Preferred Stock, converted into 37,760 shares of Series D-1 Preferred Stock on that date. Each Series D-1 share is convertible into ten shares of common stock, so the conversion corresponds to 377,600 shares of common stock. Following the transaction, Mr. Pershing beneficially owned 2,418,447 shares of common stock. The Series D-1 will automatically convert to common on June 20, 2026 unless earlier converted under its terms.
Positive
- None.
Negative
- None.
Insights
TL;DR: CEO converted a $100,000 promissory note into preferred stock that represents 377,600 common shares; ownership now 2,418,447 shares.
The transaction replaced an 8% unsecured debt obligation with equity via conversion into Series D-1 Preferred Stock at a $2.862 conversion price, then into an equity-equivalent of 377,600 common shares. This reduces on-balance-sheet debt from this instrument and increases potential common share count if conversion occurs. The filing documents the mechanical conversion and the reporting person's post-transaction beneficial ownership; no cash proceeds or additional terms beyond conversion mechanics are disclosed in the filing.
TL;DR: Insider (CEO/Director) executed a standard conversion of a convertible note into preferred stock, recorded per Section 16 reporting rules.
The Form 4 discloses a single insider transaction converting the 2024 Note into Series D-1 Preferred Stock and the related common share equivalence. The filing clarifies automatic conversion timing (June 20, 2026) and conversion ratio (1 preferred to 10 common). This is a disclosure of ownership change rather than a new issuance event; it provides transparency on insider holdings and potential future voting/dilution outcomes tied to the preferreds conversion schedule.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | 8% Unsecured Convertible Promissory Note | 0 | $0.00 | -- |
| Exercise | Series D-1 Convertible Preferred Stock | 37,760 | $0.00 | -- |
Footnotes (1)
- Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock. The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "2024 Note") at any time while the 2024 Note was outstanding into shares of Series D-1 Convertible Preferred Stock at a price per share equal to $2.862. The outstanding principal and interest of the 2024 Note automatically converted into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the 2024 Note. The 2024 Note was issued pursuant to the Issuer's 2024 Financing. On September 19, 2025, the 2024 Note was converted into 37,760 shares of Series D-1 Preferred Stock.
